Effect of a Fermented Dairy Protein With Prebiotic Fiber on GI Complaints
Arizona State University · with FrieslandCampina N.V. · NCT06946017
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–50 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 114
- US sites recruiting
- 1
- Study start
- March 31, 2025
- Record last updated
- May 8, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
A positive impact of a fermented dairy protein with prebiotic fiber supplement on self-reported GI complaints and wellbeing has been suggested (Wardenaar et al. 2024). The following project aims to further investigate the impact of this supplements in athletes with and without GI complaints in two separate data collections.
Part I of the data collection aims to investigate the impact of this supplement vs. a placebo on carbohydrate malabsorption (as a potential cause for GI distress) in athletes that normally don't identify as having GI complaints (randomized double-blind cross over study design covering a total of 9 weeks, including a 3-week washout period).
Part II of the data collection aims to confirm the earlier found results in the previous study (Wardenaar et al. 2024) in a group athletes self-reporting GI complaints that will be randomized into an intervention group or a placebo group (randomized double-blind parallel study design covering a total of 3 weeks).
Being studied: Fermented dairy protein with prebiotic fiber supplement; Control placebo
Conditions: Digestive Health; Quality of Life
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Aside from having participants fitting the inclusion and exclusion criteria below, potential participants will be screened using the gastrointestinal symptom rating scale (GSRS). Based on the outcome they will be assigned to the Part I (i.e. no self-reported GI tract issues (GSRS questionnaire score GI complaints, based on GSRS screening with all items scored \<4 (severe) and a total GSRS score ≤25), or Part II (i.e. Severe self-reported GI tract issues (GSRS questionnaire score GI complaints, based on GSRS screening with at least one item scored ≥4 (severe) and a total GSRS score ≥30). If they don't fit these criteria (i.e., having a GSRS score ranging from 26-29) they will be excluded from participation.
Inclusion Criteria
- Healthy subjects living in the Phoenix area in AZ, USA during the study
- Women/Men aged between 18-50 years (50-50%)
- Recreational competitive and non-competitive athletes (exercise at least 2x per week with a minimal total duration of 2 hours/week)
- BMI value between ≥18.5 and ≤ 30 kg/m2
- No physical limitations due to an injury (i.e., able to perform all activities associated with daily living and exercise in an independent manner).
- Willing to slightly increase their energy intake via a supplement during the study period on daily basis in the morning before breakfast.
- Willing and comfortable to perform multiple physical (stress) tests on a treadmill during the study.
- Participants without any contraindications when scoring the Physical Activity Readiness Questionnaire (PAR-Q+).
- Written informed consent
- For part I: Self-perceived lactose intolerance, and/or omission of dairy products, and/or identifying as Hispanic/Latino or Asian
- For part I: Determined to be lactase non-persistent (LNP) CC genotype by qPCR, and/or positive lactose intolerance test (>20ppm increase from baseline when 25g of lactose administered)
Exclusion Criteria
- Users of (sport) supplements containing probiotics and/or prebiotics and those unwilling to temporarily stop use of these supplements at least 3 weeks prior to start of the intervention
- Women who plan to start or stop the use of contraceptives before or during study period
- Women that have additional or worse GI symptoms during their period that can be classified as severe
- Smoking
- Clinical lactose intolerance
- Clinical or self-perceived milk protein allergy
- Diagnosed GI tract disorders or diseases
- Musculoskeletal disorders
- Diagnosed metabolic disorders (such as diabetes)
- Use of any medications known to affect protein metabolism (i.e., corticosteroids, non-steroidal anti-inflammatories, or prescribed acne medications).
- Chronic use of gastric acid suppressing medication or anti-coagulants
- Chronic use of anti-inflammatory medication
- Use of antibiotics the past 0-6 months
- Blood donation in the past 2 months
- (Intending to become) Pregnant/lactating women
- Significant changes in body weight during the past 4 weeks (i.e., due to reduction of body weight through limiting caloric intake, illness,)
- Athletes should not aim to lose bodyweight by reducing energy intake during the study
- For Part I: A hydrogen breath peak of less than 20 ppm over baseline during a lactose tolerance test
Recruiting US locations
ASU Health Futures Center
Phoenix, AZ 85054
Site contact: Kinta Schott, MS · 602-543-1853 · kschott3@asu.edu
Study contacts (from the official record)
- Floris C Wardenaar, PhD · 602-543-1853 · Floris.wardenaar@asu.edu
- Kinta Schott, MS · kschott3@asu.edu
Similar studies in Arizona
All nutrition & metabolism studies in Arizona →- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
Developing Biomarkers of Dietary Intake: Dose Dependent Measurement of Sugar Intake
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Location
- Phoenix, AZ
- Eligibility basics
- Ages 18–65
- RecruitingHealthy volunteers
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
Cleerly, Inc.
- Location
- Chandler, AZ + 121 other US sites
- Eligibility basics
- Ages 55+
- RecruitingPhase 3
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
Hoffmann-La Roche
- Location
- Chandler, AZ + 121 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
Hoffmann-La Roche
- Location
- Chandler, AZ + 112 other US sites
- Eligibility basics
- Ages 18–75